These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35114509)

  • 1. Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition.
    Cantini L; Laniado I; Murthy V; Sterman D; Aerts JGJV
    Lung Cancer; 2022 Mar; 165():91-101. PubMed ID: 35114509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
    Metro G; Signorelli D; Pizzutilo EG; Giannetta L; Cerea G; Garaffa M; Friedlaender A; Addeo A; Mandarano M; Bellezza G; Roila F
    Hum Vaccin Immunother; 2021 Sep; 17(9):2972-2980. PubMed ID: 34003722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges.
    Parikh K; Hendriks LEL; Bironzo P; Remon J
    Cancer Treat Rev; 2021 Sep; 99():102250. PubMed ID: 34174669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
    Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
    J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tsunami of immunotherapy reaches mesothelioma.
    Mielgo-Rubio X; Cardeña Gutiérrez A; Sotelo Peña V; Sánchez Becerra MV; González López AM; Rosero A; Trujillo-Reyes JC; Couñago F
    World J Clin Oncol; 2022 Apr; 13(4):267-275. PubMed ID: 35582652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab for the treatment of unresectable pleural mesothelioma.
    Hotta K; Fujimoto N; Kozuki T; Aoe K; Kiura K
    Expert Opin Biol Ther; 2020 Feb; 20(2):109-114. PubMed ID: 31825692
    [No Abstract]   [Full Text] [Related]  

  • 7. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
    Peters S; Scherpereel A; Cornelissen R; Oulkhouir Y; Greillier L; Kaplan MA; Talbot T; Monnet I; Hiret S; Baas P; Nowak AK; Fujimoto N; Tsao AS; Mansfield AS; Popat S; Zhang X; Hu N; Balli D; Spires T; Zalcman G
    Ann Oncol; 2022 May; 33(5):488-499. PubMed ID: 35124183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
    Hotta K; Fujimoto N
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32098830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma.
    Ye ZM; Tang ZQ; Xu Z; Zhou Q; Li H
    Front Public Health; 2022; 10():947375. PubMed ID: 35937220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma.
    Borgeaud M; Kim F; Friedlaender A; Lococo F; Addeo A; Minervini F
    J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
    Cui W; Popat S
    Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights.
    López-Castro R; Fuentes-Martín Á; Medina Del Valle A; García Peña T; Soro García J; López González L; Cilleruelo Ramos Á
    Open Respir Arch; 2024; 6(3):100323. PubMed ID: 38660145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature.
    Reveneau MF; Masliah-Planchon J; Fernandez M; Ouikene A; Dron B; Dadamessi I; Dayen C; Golmard L; Chauffert B
    Front Oncol; 2024; 14():1410322. PubMed ID: 39091916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
    Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
    Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy.
    Cedres S; Valdivia A; Iranzo P; Callejo A; Pardo N; Navarro A; Martinez-Marti A; Assaf-Pastrana JD; Felip E; Garrido P
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapeutic Approaches in Malignant Pleural Mesothelioma.
    Terenziani R; Zoppi S; Fumarola C; Alfieri R; Bonelli M
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment.
    Gounant V; Brosseau S; Zalcman G
    Ther Adv Med Oncol; 2021; 13():17588359211061956. PubMed ID: 34917175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma.
    Brockwell NK; Alamgeer M; Kumar B; Rivalland G; John T; Parker BS
    Transl Lung Cancer Res; 2020 Jun; 9(3):639-645. PubMed ID: 32676326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
    Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
    Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
    Baas P; Scherpereel A; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Jahan T; Antonia S; Oulkhouir Y; Bautista Y; Cornelissen R; Greillier L; Grossi F; Kowalski D; Rodríguez-Cid J; Aanur P; Oukessou A; Baudelet C; Zalcman G
    Lancet; 2021 Jan; 397(10272):375-386. PubMed ID: 33485464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.